Moss, 18 February 2021

Gentian Diagnostics AS today announces that its patent application for a highly
sensitive particle enhanced assay for the quantification of NT-proBNP has been
published by the World Intellectual Property Organization (PCT Application No.
PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in
this patent application enables Gentian to develop and commercialize an
automated and fast NT-proBNP assay for open turbidimetric clinical chemistry
platforms.

The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of
congestive heart failure (CHF), is planned for 4Q 2021. The assay under
development by Gentian Diagnostics will enable improvement of laboratory
productivity based on higher throughput in comparison to currently used assays
and contribute to the harmonization and standardization of the NT-proBNP assays.


Going forward, the Company will announce when patents are granted.  

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242


Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525